Alzinova takes the next step towards a phase II study in the US
Börskollen - Aktier, fonder och ekonominyheter
BörskollenFör dig med koll på börsen

Pressmeddelande

Alzinova takes the next step towards a phase II study in the US

MFN Publicerad: 12 Aug 13:39

Alzinova has taken a significant step towards starting its planned phase II study with ALZ-101 by submitting a Clinical Trial Application (IND) to the US Food and Drug Administration (FDA). At the same time, the company has applied for Fast Track designation, which can accelerate the development of the therapeutic vaccine against Alzheimer’s disease. We contacted CEO Tord Labuda for a comment.

Read the full interview with Tord Labuda at biostock.se:

https://biostock.se/en/2025/08/alzinova-takes-the-next-step-towards-a-phase-ii-study-in-the-us/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läses av andra just nu

Senaste nytt